In vivo quantification of active decitabine-triphosphate metabolite: A novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 242-249

  Wang, Hongyan ^a,c   Chen, Ping ^a,d   Wang, Jiang ^a   Santhanam, Ramasamy ^b   Aimiuwu, Josephine ^a   Saradhi, U V Vijaya ^a   Liu, Zhongfa ^a   Schwind, Sebastian ^b,c   Mims, Alice ^b   Byrd, John C ^b,c   Grever, Michael R ^b,c   Villalona Calero, Miguel A ^b,c   Klisovic, Rebecca ^b,c   Walker, Alison ^b,c   Garzon, Ramiro ^b,c   Blum, William ^b,c   Chan, Kenneth K ^a,b,c   Marcucci, Guido ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d AMGEN INC   (United States)

Author keywords

acute myeloid leukemia; decitabine; metabolite; quantification method; triphosphate

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DECITABINE TRIPHOSPHATE; DNA; DNA METHYLTRANSFERASE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CANCER RESISTANCE; DNA METHYLATION; DOWN REGULATION; DRUG ACTIVATION; DRUG ACTIVITY; DRUG BINDING; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG RESPONSE; ENZYME INACTIVATION; ENZYME REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MONONUCLEAR CELL; MOUSE; NONHUMAN; SPLEEN; TANDEM MASS SPECTROMETRY; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA MODIFICATION METHYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; POLYPHOSPHATES;

EID: 84871977827     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9427-5     Document Type: Article

References (25)

1. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-91. (Pubitemid 47477265)
2. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473-8.
3. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-61.
4. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-96.
5. Lubbert M, Ruter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3):393-401.
6. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995;67(2):155-86.
7. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood. 2009;113(3):659-67.
8. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One. 2011;6(8):e23372.
9. Wu JC, Santi DV. Kinetic and catalytic mechanism of HhaI methyltransferase. J Biol Chem. 1987;262(10):4778-86. (Pubitemid 17102852)
10. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, et al. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods. 2005;2(10):751-6. (Pubitemid 41486206)
11. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 2010;38(13):4313-24.
12. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008;112(5):2013-6.
13. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom. 2006;20(7):1117-26.
14. Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, et al. A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels. Pharm Res. 2009;26(6):1504-15.
15. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411-8.
16. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008;111(4):2364-73. (Pubitemid 351451445)
17. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet. 2011;7(2):e1001286.
18. Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK, et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci USA. 2004;101(3):817-22. (Pubitemid 38121041)
19. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, et al. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 2012;26(3):443-50.
20. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483-95. (Pubitemid 34983483)
21. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12(19):5777-85. (Pubitemid 44629609)
22. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333-47.
23. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16(4):249-55.
24. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000;17(12):1551-7. (Pubitemid 32217566)
25. Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemother Pharmacol. 2012;69(6):1457-66.